GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycenax Biotech Inc (ROCO:4726) » Definitions » Cyclically Adjusted Price-to-FCF

Mycenax Biotech (ROCO:4726) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Mycenax Biotech Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Mycenax Biotech Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Mycenax Biotech's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycenax Biotech Cyclically Adjusted Price-to-FCF Chart

Mycenax Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mycenax Biotech Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Mycenax Biotech's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Mycenax Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mycenax Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Mycenax Biotech's Cyclically Adjusted Price-to-FCF falls into.


;
;

Mycenax Biotech Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Mycenax Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Mycenax Biotech's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.338/134.9266*134.9266
=-0.338

Current CPI (Mar. 2025) = 134.9266.

Mycenax Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.543 100.684 -0.728
201509 -0.069 100.392 -0.093
201512 -0.154 99.792 -0.208
201603 -0.923 100.470 -1.240
201606 -1.170 101.688 -1.552
201609 -0.848 101.861 -1.123
201612 -0.295 101.863 -0.391
201703 -0.647 102.862 -0.849
201706 -0.320 103.349 -0.418
201709 -0.197 104.136 -0.255
201712 -0.088 104.011 -0.114
201803 -0.585 105.290 -0.750
201806 -0.912 106.317 -1.157
201809 -0.281 106.507 -0.356
201812 -0.970 105.998 -1.235
201903 -1.607 107.251 -2.022
201906 -0.202 108.070 -0.252
201909 0.088 108.329 0.110
201912 -0.891 108.420 -1.109
202003 0.192 108.902 0.238
202006 0.208 108.767 0.258
202009 -0.962 109.815 -1.182
202012 -0.149 109.897 -0.183
202103 -0.569 111.754 -0.687
202106 -2.192 114.631 -2.580
202109 -3.766 115.734 -4.391
202112 -1.776 117.630 -2.037
202203 -0.745 121.301 -0.829
202206 -1.775 125.017 -1.916
202209 -1.762 125.227 -1.898
202212 -0.653 125.222 -0.704
202303 -0.638 127.348 -0.676
202306 -0.614 128.729 -0.644
202309 -0.219 129.860 -0.228
202312 -0.618 129.419 -0.644
202403 -1.744 131.776 -1.786
202406 -0.029 132.554 -0.030
202409 -0.261 133.029 -0.265
202412 -0.501 133.157 -0.508
202503 -0.338 134.927 -0.338

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Mycenax Biotech  (ROCO:4726) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Mycenax Biotech Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Mycenax Biotech's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycenax Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Mycenax Biotech Headlines

No Headlines